BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 11238855)

  • 1. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.
    Bleiber G; Munoz M; Ciuffi A; Meylan P; Telenti A
    J Virol; 2001 Apr; 75(7):3291-300. PubMed ID: 11238855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of human immunodeficiency virus type-1 (HIV-1) particles that express protease-reverse transcriptase fusion proteins.
    Cherry E; Liang C; Rong L; Quan Y; Inouye P; Li X; Morin N; Kotler M; Wainberg MA
    J Mol Biol; 1998 Nov; 284(1):43-56. PubMed ID: 9811541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of HIV constructs containing protease-reverse transcriptase fusion proteins on viral replication.
    Cherry E; Morin N; Wainberg MA
    AIDS; 1998 Jun; 12(9):967-75. PubMed ID: 9662192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants.
    Dykes C; Fox K; Lloyd A; Chiulli M; Morse E; Demeter LM
    Virology; 2001 Jul; 285(2):193-203. PubMed ID: 11437654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein.
    Peters S; Muñoz M; Yerly S; Sanchez-Merino V; Lopez-Galindez C; Perrin L; Larder B; Cmarko D; Fakan S; Meylan P; Telenti A
    J Virol; 2001 Oct; 75(20):9644-53. PubMed ID: 11559796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cotransfection of mutated forms of human immunodeficiency virus type 1 Gag-Pol with wild-type constructs can interfere with processing and viral replication.
    Morin N; Cherry E; Li X; Wainberg MA
    J Hum Virol; 1998; 1(3):240-7. PubMed ID: 10195247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection.
    Simon V; Padte N; Murray D; Vanderhoeven J; Wrin T; Parkin N; Di Mascio M; Markowitz M
    J Virol; 2003 Jul; 77(14):7736-45. PubMed ID: 12829813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding region.
    Villena C; Prado JG; Puertas MC; Martínez MA; Clotet B; Ruiz L; Parkin NT; Menéndez-Arias L; Martinez-Picado J
    J Virol; 2007 May; 81(9):4713-21. PubMed ID: 17314158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1.
    Garcia-Perez J; Sanchez-Palomino S; Perez-Olmeda M; Fernandez B; Alcami J
    J Med Virol; 2007 Feb; 79(2):127-37. PubMed ID: 17177310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
    Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
    J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle.
    Witvrouw M; Fikkert V; Pluymers W; Matthews B; Mardel K; Schols D; Raff J; Debyser Z; De Clercq E; Holan G; Pannecouque C
    Mol Pharmacol; 2000 Nov; 58(5):1100-8. PubMed ID: 11040059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The roles of the human immunodeficiency virus type 1 Pol protein and the primer binding site in the placement of primer tRNA(3Lys) onto viral genomic RNA.
    Liang C; Rong L; Morin N; Cherry E; Huang Y; Kleiman L; Wainberg MA
    J Virol; 1997 Dec; 71(12):9075-86. PubMed ID: 9371564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
    Naeger LK; Margot NA; Miller MD
    Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of the Gag-Pol transframe domain p6* and its coding sequence to morphogenesis and replication of human immunodeficiency virus type 1.
    Paulus C; Ludwig C; Wagner R
    Virology; 2004 Dec; 330(1):271-83. PubMed ID: 15527852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect.
    Jeeninga RE; Keulen W; Boucher C; Sanders RW; Berkhout B
    Virology; 2001 May; 283(2):294-305. PubMed ID: 11336554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
    J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV type 1 protease cleavage site mutations and viral fitness: implications for drug susceptibility phenotyping assays.
    Robinson LH; Myers RE; Snowden BW; Tisdale M; Blair ED
    AIDS Res Hum Retroviruses; 2000 Aug; 16(12):1149-56. PubMed ID: 10954890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new strategy based on recombinant viruses for assessing the replication capacity of HIV-1.
    Garcia-Perez J; Perez-Olmeda M; Sanchez-Palomino S; Perez-Romero P; Alcami J
    HIV Med; 2008 Mar; 9(3):160-71. PubMed ID: 18217999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease.
    Goodenow MM; Bloom G; Rose SL; Pomeroy SM; O'Brien PO; Perez EE; Sleasman JW; Dunn BM
    Virology; 2002 Jan; 292(1):137-49. PubMed ID: 11878916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
    Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
    Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.